Aurisco(605116)2024-04-28 07:47Financial Performance - The total revenue for the cardiovascular raw materials segment reached ¥300,413,911.15, representing a 26.94% increase compared to the previous year[21]. - The gross profit margin for the oncology raw materials segment was 43.33%, with a revenue increase of 73.63% year-over-year[21]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the last fiscal year, representing a growth of 20% year-over-year[133]. - The company reported a revenue of 1.5 billion RMB for the fiscal year 2023, representing a year-over-year growth of 15%[136]. - The company has set a revenue guidance for the next fiscal year at 1.8 billion RMB, which reflects an expected growth of 20%[136]. - The company provided guidance for the next fiscal year, projecting revenue growth of 25% and aiming to reach 1.875 billion[133]. Research and Development - Research and development expenses decreased by 31.26% to ¥40,992,447.18 compared to the previous year[5]. - The company's R&D investment amounted to 6,707.27 million RMB, representing 8.77% of operating revenue and 4.59% of net assets[26]. - The average R&D investment in the same industry was 35,786.23 million RMB, with the company's R&D investment accounting for 10.84% of operating revenue and 6.96% of net assets during the reporting period[26]. - The company is focusing on technological innovation and cost reduction in existing products while seeking breakthroughs in new products[83]. - The company is focusing on developing new products in the raw material and formulation projects, with multiple new projects initiated in 2023[27]. - The company has 36 products currently under research, with multiple new products expected to enter the registration application stage in the next 3-5 years[83]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficacy and safety[136]. - The company has established six major engineering technology innovation platforms for the research and development of small molecule drugs, peptide drugs, and oligonucleotide drugs[56]. - The company has a professional research team composed of PhD, master's, and bachelor's degree holders, equipped with advanced R&D testing equipment including UPLC-MS and GC-MS[147]. Marketing and Sales - The company plans to expand its marketing network and strengthen customer relationships while penetrating markets in Europe, America, and Asia[38]. - Over 85% of the company's products were sold overseas during the reporting period, indicating a strong international market presence[64]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of the next fiscal year[133]. - A new strategic partnership was announced, expected to enhance distribution channels and increase sales by 15%[133]. - The company's marketing team utilizes various methods for market expansion, including global pharmaceutical exhibitions and customer visits[167]. Environmental and Safety Management - The company invested 2,874.48 million RMB in environmental protection in 2023, with plans to increase this investment in the future[41]. - The company is committed to improving its EHS management system to mitigate environmental and safety risks associated with its production processes[41]. - The company has established a standardized hazardous waste storage area with a total area of 380 m²[155]. - The company has implemented various wastewater and waste gas treatment processes, ensuring compliance with environmental standards[155][157]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[152]. - The company has undergone changes in its board of directors, with several independent directors being elected or replaced[160]. Governance and Compliance - The company emphasizes the importance of internal control and governance, ensuring compliance with relevant laws and regulations[65]. - The company has established a comprehensive and effective internal control system, ensuring all subsidiaries maintained effective internal controls without significant defects during the reporting period[127]. - The company received a standard unqualified opinion in its internal control audit report for 2023[151]. - The company has implemented corrective measures for identified management issues to continuously improve its internal control system[127]. - The company has a diverse board with members holding various positions in other companies, enhancing its strategic oversight capabilities[124]. Shareholder Returns - The company plans to distribute a cash dividend of RMB 2.20 per 10 shares for the 2023 fiscal year, totaling RMB 89.3629 million, subject to shareholder approval[92]. - The company has approved a three-year shareholder return plan for 2023-2025 during the shareholder meeting[1]. - The company has a cash dividend policy that stipulates a minimum of 20% of the distributable profit should be distributed in cash if conditions allow[116]. - The company declared a cash dividend of 2.20 RMB per 10 shares, totaling 89,362,900 RMB, which represents 30.88% of the net profit attributable to ordinary shareholders in the consolidated financial statements[96]. Operational Efficiency - The company is focusing on enhancing production efficiency and product quality stability through continuous optimization of existing leading products[56]. - The company aims to improve operational efficiency by 15% through the implementation of advanced manufacturing technologies[136]. - The company has implemented upgrades to its waste gas treatment facilities, improving operational efficiency and treatment effectiveness[177]. Financial Management - The net cash flow from financing activities for 2023 was ¥49,019,558.18, compared to a negative ¥14,914,942.10 in the previous period[149]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to ¥17,156,238[159]. - The company plans to issue convertible bonds to raise funds for future projects, with a feasibility analysis report approved by the board[141].